The French company Sensorion has been forced to delay a phase II trial in people with hearing loss due to slow patient recruitment amid the current coronavirus disease (Covid-19) pandemic.
The clinical trial is designed to test Sensorion’s lead candidate drug in people with sudden sensorineural hearing loss, a rare disorder where the patient can go deaf within several days. The trial results were to be released late 2020, but the company now expects to release them in mid-2021.
Nawal Ouzren, CEO of Sensorion, stated that slow patient recruitment caused the delay, as well as hospital resources being reprioritized to handle the Covid-19 outbreak. The global outbreak — labeled a pandemic by the World Health Organization last week — threatens to overwhelm healthcare systems around the world without an effective vaccine or drug approved for the disease.
The company stated that it will keep monitoring the Covid-19 situation, which is changing very quickly. “We are doing our utmost to ensure we can provide the clinical data set as quickly as possible,” stated Géraldine Honnet, Sensorion’s CMO.
Sudden sensorineural hearing loss occurs when the sensory hair cells in the inner ear are destroyed, most often for an unknown reason.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed